Kopetz S - Search Results

1

Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.

Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F. Zhao M, et al. Among authors: kopetz s. Clin Cancer Res. 2021 Mar 15;27(6):1681-1694. doi: 10.1158/1078-0432.CCR-20-3017. Epub 2021 Jan 7. Clin Cancer Res. 2021. PMID: 33414137 Free PMC article.

2

Src continues aging: current and future clinical directions.

Kopetz S, Shah AN, Gallick GE. Kopetz S, et al. Clin Cancer Res. 2007 Dec 15;13(24):7232-6. doi: 10.1158/1078-0432.CCR-07-1902. Clin Cancer Res. 2007. PMID: 18094400 Review.

3

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.

Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Kopetz S, et al. J Clin Oncol. 2008 Apr 20;26(12):2000-5. doi: 10.1200/JCO.2007.13.2407. J Clin Oncol. 2008. PMID: 18421052

4

A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.

Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. Hoff PM, et al. Among authors: kopetz s. Br J Cancer. 2008 Sep 2;99(5):722-6. doi: 10.1038/sj.bjc.6604541. Epub 2008 Aug 12. Br J Cancer. 2008. PMID: 18728662 Free PMC article. Clinical Trial.

5

Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.

Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Overman MJ, et al. Among authors: kopetz s. Cancer. 2008 Oct 15;113(8):2038-45. doi: 10.1002/cncr.23822. Cancer. 2008. PMID: 18759326 Free article.

6

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.

Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Kesmodel SB, et al. Among authors: kopetz s. J Clin Oncol. 2008 Nov 10;26(32):5254-60. doi: 10.1200/JCO.2008.17.7857. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854565

7

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Kopetz S, et al. Cancer Res. 2009 May 1;69(9):3842-9. doi: 10.1158/0008-5472.CAN-08-2246. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383922 Free PMC article.

8

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Overman MJ, et al. Among authors: kopetz s. Br J Cancer. 2010 Jan 5;102(1):144-50. doi: 10.1038/sj.bjc.6605449. Epub 2009 Nov 24. Br J Cancer. 2010. PMID: 19935793 Free PMC article.

9

The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.

Lieu C, Kopetz S. Lieu C, et al. Among authors: kopetz s. Clin Colorectal Cancer. 2010 Apr;9(2):89-94. doi: 10.3816/CCC.2010.n.012. Clin Colorectal Cancer. 2010. PMID: 20378502 Free PMC article. Review.

10

PI-3-Kinase inhibitors in colorectal cancer.

Ihle NT, Powis G, Kopetz S. Ihle NT, et al. Among authors: kopetz s. Curr Cancer Drug Targets. 2011 Feb;11(2):190-8. doi: 10.2174/156800911794328448. Curr Cancer Drug Targets. 2011. PMID: 21158718 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

444 results

Search Page